US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Antibody Therapeutics | 04/11/2025 | By Dineshwori
Harbour BioMed Names Yajie Li as Chief Medical Officer
As Chief Medical Officer (CMO), Yajie Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
Antibody Therapeutics | 25/08/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy